Ninety-nine percent of molecules developed in the lab never make it to market - a fact all too real for pharmaceutical companies, academic institutions, and the National Institutes of Health. Eli Lilly and Company announced at the end of November 2016 that their investigational medicine solanezumab did not succeed in the last stage of clinical testing for mild dementia due to Alzheimer’s.
In the face of setbacks, it's important to understand the resources, research, and tests that go into bringing this type of medicine to market. It takes decades, billions of dollars, and the dedication of trial participants to name just a few.
There is no medicine yet approved to slow, cure, or prevent Alzheimer's disease. Lilly is committed to changing that. As they continue the search, learn why the arduous process of championing a new treatment — from test tube to patient -— is forever worth the journey.
